期刊文献+

2型糖尿病急性冠脉综合征患者Lp-PLA2水平和GRACE评分及其与主要心血管不良事件相关性

Lp-PLA2 and GRACE scores in patients with type 2 diabetes and acute coronary syndrome and their association with major adverse cardiovascular events
原文传递
导出
摘要 目的探讨2型糖尿病急性冠脉综合征(ACS)患者脂蛋白相关磷脂酶A2(Lp-PLA2)水平和全球急性冠状动脉事件注册(GRACE)评分及其与主要心血管不良事件(MACE)的关系。方法选取2016-03-01-2020-05-31泰州市中西医结合医院接受治疗的103例2型糖尿病ACS患者为研究对象。所有患者出院后随访90 d,根据是否发生MACE事件分为事件组(n=17)和非事件组(n=86)。比较2组性别、年龄、吸烟、饮酒、收缩压、舒张压、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、同型半胱氨酸(Hcy)水平、药物使用情况、Lp-PLA2水平、GRACE评分。采用多因素分析,筛选患者发生MACE事件的独立危险因素。结果单因素分析结果显示,事件组与非事件组比较,年龄(t=3.067,P<0.001)、性别(t=4.023,P=0.044)、HDL-C(t=5.072,P<0.001)、Lp-PLA2水平(t=8.427,P<0.001)、Hcy水平(t=4.121,P<0.001)和GRACE评分(t=6.470,P<0.001)之间差异有统计学意义。多因素Logistic回归分析结果显示,发生MACE事件的危险因素是Lp-PLA2水平(OR=2.098,95%CI为1.318~3.324,P<0.001)和GRACE评分(OR=2.431,95%CI为1.309~4.513,P<0.001)。结论2型糖尿病ACS患者Lp-PLA2水平升高,与GRACE评分呈正相关。Lp-PLA2水平和GRACE评分是患者发生MACE事件的独立危险因素。 Objective To investigate the level of lipoprotein associated phospholipase A2(Lp-PLA2)and global register of acute coronary events(GRACE)score in patients with type 2 diabetes mellitus with acute coronary syndrome(ACS)and their relationship with major adverse cardiovascular events(MACE).Methods A total of 103 patients with type 2 diabetes ACS who received treatment in Taizhou Hospital of Integrated Chinese and Western Medicine from March 1,2016 to May 31,2020 were selected as the subjects.All patients were followed up for 90 days after discharge.They were divided into event group(n=17)and non event group(n=86).The levels of gender,age,smoking,drinking,systolic blood pressure,diastolic blood pressure,triglyceride(TG),total cholesterol(TC),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),homocysteine(Hcy),drug use,Lp-PLA2 and GRACE score were compared between the two groups.Multivariate analysis was used to screen the independent risk factors of MACE events.Results Univariate analysis showed that there were significant differences in age(t=3.067,P<0.001),gender(t=4.023,P=0.044),HDL-C(t=5.072,P<0.001),Lp-PLA2 level(t=8.427,P<0.001),Hcy level(t=4.121,P<0.001)and GRACE score(t=6.470,P<0.001)between event group and non event group.Multivariate Logistic regression analysis showed that the risk factors of mace events were Lp-PLA2 level(OR=2.098,95%CI:1.318-3.324,P<0.001)and grace score(OR=2.431,95%CI:1.309-4.513,P<0.001).Conclusion The level of Lp-PLA2 in patients with type 2 diabetes mellitus is elevated,and is positively correlated with GRACE score in ACS patients.Lp-PLA2 level and grace score were independent risk factors for mace events.
作者 刘剑峰 陈梅 LIU Jian-feng;CHEN Mei(Department of Geriatric,Taizhou Hospital of Integrated Chinese and Western Medicine,Taizhou 225300,China)
出处 《社区医学杂志》 CAS 2022年第2期83-86,共4页 Journal Of Community Medicine
关键词 脂蛋白相关磷脂酶A2 糖尿病 全球急性冠状动脉事件注册评分 主要心血管不良事件 急性冠脉综合征 lipoprotein associated phospholipase A2 diabetes global register of acute coronary events score major adverse cardiovascular events acute coronary syndrome
作者简介 通信作者:刘剑峰,男,江苏泰兴人,副主任医师,主要从事高血压及糖尿病等疾病的诊治研究工作。E-mail:yzca49@163.com
  • 相关文献

参考文献16

二级参考文献184

  • 1孔艳艳,刘楠,姜新,陈晓虹.急性脑梗死患者血浆NT-proBNP临床意义[J].中国实用内科杂志,2013,33(S1):114-117. 被引量:11
  • 2郝恒剑,李耘,李康,魏嘉平,汪家瑞.急性下壁心肌梗死合并完全性房室阻滞患者冠状动脉病变的特点及临床预后[J].中国循环杂志,2004,19(4):255-257. 被引量:2
  • 3刘甲兴,郑兴,秦永文,丁继军,赵仙先,曹江.脂蛋白相关性磷脂酶A_2活性能反映冠状动脉粥样硬化病变程度[J].第二军医大学学报,2006,27(4):391-395. 被引量:31
  • 4洪衡,王明生,王河,李明昌,王磊,肖毅,杨光,王红梅,任海明,贾宁,谭丽玲,顼志敏.不同类型急性心肌梗死冠状动脉病变特点的观察[J].中国循环杂志,2007,22(3):187-190. 被引量:11
  • 5Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25: 923-931.
  • 6Waxman S, Ishibashi F, Muller JE. Detection and treatment of vulnerable plaques and vulnerable patients: novel approaches to prevention of coronary events. Circulation 2006; 114: 2390-2411.
  • 7Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vase Biol 2006; 26: 2523-2529.
  • 8Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14: 1059-1066.
  • 9Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101 (12A): 41F-50E.
  • 10Koenig W, Khuseyinova N. Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 2009; 23: 85-92.

共引文献360

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部